WeHealth by Servier and PathMaker Neurosystems Form Partnership for a Breakthrough Non-Invasive Neuromodulation Device for the Treatment of Spasticity
1/9/19: As part of the agreement, WeHealth will fund a recently initiated European clinical trial evaluating MyoRegulator for non-invasive treatment of spasticity secondary to stroke, which is currently being conducted by France’s prestigious Brain and Spine Institute (Institut du Cerveau et de la Moelle Epinière – ICM) at the Pitié-Salpêtrière Hospital in Paris.
Initiation of Landmark European Clinical Trial Evaluating MyoRegulator™ for Non-Invasive Treatment of Spasticity Announces PathMaker Neurosystems
9/5/18: “This trial is yet another milestone for PathMaker as we advance our development strategy to rapidly bring to market an entirely novel, non-invasive approach to treating spasticity,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. “We expect the results from this trial and our U.S. trial to enable regulatory approvals in both Europe and the U.S.”